Clinical TrialsAstria's lead asset STAR-0215 shows potential to be at least as effective as market leader Takhzyro, but with a more convenient dosing interval of every three or six months.
Efficacy And Safety DataAstria posted impressive six-month efficacy and safety data from its ALPHA-STAR Phase 1b/2 with STAR-0215, significantly de-risking the program for the upcoming pivotal Phase 3 trial.
Financial StrengthThe company ended the quarter financially strong with $369.9 million, which management believes is sufficient to fund current operations into mid-2027.